WO2001078785A3 - Wirkstoff-konjugate mit intrazellulär wirksamen liganden - Google Patents

Wirkstoff-konjugate mit intrazellulär wirksamen liganden Download PDF

Info

Publication number
WO2001078785A3
WO2001078785A3 PCT/DE2001/001495 DE0101495W WO0178785A3 WO 2001078785 A3 WO2001078785 A3 WO 2001078785A3 DE 0101495 W DE0101495 W DE 0101495W WO 0178785 A3 WO0178785 A3 WO 0178785A3
Authority
WO
WIPO (PCT)
Prior art keywords
active
intracellularly
ligands
substance conjugates
active substance
Prior art date
Application number
PCT/DE2001/001495
Other languages
English (en)
French (fr)
Other versions
WO2001078785A2 (de
Inventor
Stefan Duebel
Frank Emmrich
Original Assignee
Biotectid Gmbh
Stefan Duebel
Frank Emmrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotectid Gmbh, Stefan Duebel, Frank Emmrich filed Critical Biotectid Gmbh
Priority to DE10191398T priority Critical patent/DE10191398D2/de
Priority to AU73844/01A priority patent/AU7384401A/en
Publication of WO2001078785A2 publication Critical patent/WO2001078785A2/de
Publication of WO2001078785A3 publication Critical patent/WO2001078785A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft Wirkstoff-Konjugate mit einem intrazellulär wirksamen Liganden, einer Targeting-Domäne sowie meist auch einer den Eintritt ins Cytoplasma der Zielzelle gewährleistenden Lokalisations-Domäne sowie deren Verwendung als Diagnostikum und Arzneimittel auch in verschiedenen Indikationen sowie Verfahren zu deren Herstellung.
PCT/DE2001/001495 2000-04-18 2001-04-18 Wirkstoff-konjugate mit intrazellulär wirksamen liganden WO2001078785A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE10191398T DE10191398D2 (de) 2000-04-18 2001-04-18 Wirkstoff-Konjugate mit Intrazellulär wirksamen Liganden
AU73844/01A AU7384401A (en) 2000-04-18 2001-04-18 Active substance conjugates with intracellularly active ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10019157.6 2000-04-18
DE10019157A DE10019157A1 (de) 2000-04-18 2000-04-18 Verfahren zum Einbringen von Liganden in lebende Zellen

Publications (2)

Publication Number Publication Date
WO2001078785A2 WO2001078785A2 (de) 2001-10-25
WO2001078785A3 true WO2001078785A3 (de) 2002-05-10

Family

ID=7639155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/001495 WO2001078785A2 (de) 2000-04-18 2001-04-18 Wirkstoff-konjugate mit intrazellulär wirksamen liganden

Country Status (3)

Country Link
AU (1) AU7384401A (de)
DE (2) DE10019157A1 (de)
WO (1) WO2001078785A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1205191A1 (de) * 2000-11-13 2002-05-15 Centre National De La Recherche Scientifique Zielgerichte Änderung von intrazellular Verbindungen
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
DE102007041834A1 (de) * 2007-09-03 2009-03-05 Siemens Ag Arzneimittel zur Behandlung eines Karzinoms
JP2014505064A (ja) * 2011-01-26 2014-02-27 セニックス バイオサイエンス ゲーエムベーハー 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
BR122020006914B8 (pt) 2014-10-23 2023-01-31 Singh Biotechnology Llc Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008495A1 (en) * 1990-11-09 1992-05-29 Abbott Biotech, Inc. Cytokine immunoconjugates
WO1994004696A1 (en) * 1992-08-25 1994-03-03 Miles Inc. Translocation signal facilitated nuclear delivery of macromolecules
WO1996004305A1 (en) * 1994-08-04 1996-02-15 Menarini Ricerche S.P.A. Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions
EP0706799A2 (de) * 1994-09-16 1996-04-17 MERCK PATENT GmbH Immunokonjugate
WO1998042876A1 (en) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
WO2000045850A2 (en) * 1999-02-06 2000-08-10 Aurx Inc. Drug delivery vehicle
WO2001053336A1 (en) * 2000-01-19 2001-07-26 Allergan Sales, Inc. Clostridial toxin derivatives and methods for treating pain

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008495A1 (en) * 1990-11-09 1992-05-29 Abbott Biotech, Inc. Cytokine immunoconjugates
WO1994004696A1 (en) * 1992-08-25 1994-03-03 Miles Inc. Translocation signal facilitated nuclear delivery of macromolecules
WO1996004305A1 (en) * 1994-08-04 1996-02-15 Menarini Ricerche S.P.A. Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions
EP0706799A2 (de) * 1994-09-16 1996-04-17 MERCK PATENT GmbH Immunokonjugate
WO1998042876A1 (en) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
WO2000045850A2 (en) * 1999-02-06 2000-08-10 Aurx Inc. Drug delivery vehicle
WO2001053336A1 (en) * 2000-01-19 2001-07-26 Allergan Sales, Inc. Clostridial toxin derivatives and methods for treating pain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOMINAYA J ET AL: "A CHIMERIC FUSION PROTEIN CONTAINING TRANSFORMING GROWTH FACTOR-ALPHA MEDIATES GENE TRANSFER VIA BINDING TO THE EGF RECEPTOR", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, 1998, pages 521 - 530, XP002934101, ISSN: 0969-7128 *
FOMINAYA J ET AL: "TARGET CELL-SPECIFIC DNA TRANSFER MEDIATED BY A CHIMERIC MULTIDOMAIN PROTEIN. NOVEL NON-VIRAL GENE DELIVERY SYSTEM", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 18, 3 May 1996 (1996-05-03), pages 10560 - 10568, XP002036158, ISSN: 0021-9258 *
SCHMIDT W ET AL: "Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferrinfection (AVET)", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 190, no. 1, 29 April 1997 (1997-04-29), pages 211 - 216, XP004064404, ISSN: 0378-1119 *
WAGNER E ET AL: "COUPLING OF ADENOVIRUS TO TRANSFERRIN-POLYLYSINE/DNA COMPLEXES GREATLY ENHANCES RECEPTOR-MEDIATED GENE DELIVERY AND EXPRESSION OF TRANSFECTED GENES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, no. 13, 1 July 1992 (1992-07-01), pages 6099 - 6103, XP000561198, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
DE10019157A1 (de) 2001-11-15
AU7384401A (en) 2001-10-30
DE10191398D2 (de) 2003-04-30
WO2001078785A2 (de) 2001-10-25

Similar Documents

Publication Publication Date Title
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
WO2000056774A8 (en) Methods of using bioelastomers
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2002043580A3 (en) Production of microspheres
WO2004082628A3 (en) Improved bioavailability and improved delivery of acidic pharmaceutical drugs
IN2012DN00520A (de)
AU2002227931A1 (en) Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, their use as medicament, and pharmaceutical preparations containing these compounds
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2006113623A3 (en) Elimination of heterogeneous or mixed cell population in tumors
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
WO2001091807A3 (en) Ethylenedicysteine (ec)-drug conjugates
BR0208338A (pt) Derivados de piridina
HK1047575A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containingthe same.
GEP20094620B (en) Irinotecan preparation
WO2005113021A3 (en) Device, system and method for in-vivo analysis
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
AU7634801A (en) Three-dimensional skin model
DE50310435D1 (de) Filmförmige, zerfallsfähige zubereitungen zur wirkstoff-freisetzung und verfahren zu deren herstellung
PT1140808E (pt) Formulacoes de pesticidas contendo tensioactivos de ester de hemissulfato de tristirilfenol alcoxilado, neutralizados com amina alcoxilada
WO2004098537A3 (en) Activation agents on the surface of encapsulation vesicles
WO2001078785A3 (de) Wirkstoff-konjugate mit intrazellulär wirksamen liganden
WO1999058151A3 (en) Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells
WO2002027315A3 (en) Compounds with a branched linker
PL2089433T3 (pl) Terapia ukierunkowana na katepsynę S
WO2004112717A3 (en) Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REF Corresponds to

Ref document number: 10191398

Country of ref document: DE

Date of ref document: 20030430

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10191398

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8607